Difference between revisions of "BRST5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[checked revision][checked revision]
 
(9 intermediate revisions by the same user not shown)
Line 6: Line 6:
  
 
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
+
__TOC__
 
<br />
 
<br />
 
{| class="wikitable" style="margin:auto"
 
{| class="wikitable" style="margin:auto"
Line 19: Line 19:
 
!'''Notes'''
 
!'''Notes'''
 
|-
 
|-
|CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)
+
|
 +
====CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)====
 
|
 
|
 
----
 
----
Line 39: Line 40:
 
----
 
----
 
|-
 
|-
|Usual Ductal Hyperplasia
+
|Usual ductal hyperplasia
 
|Disease
 
|Disease
 
|
 
|
Line 50: Line 51:
 
|
 
|
 
|-
 
|-
|Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
+
|Columnar cell lesions, including flat epithelial atypia||Disease||
 
|
 
|
 
|
 
|
Line 59: Line 60:
 
|
 
|
 
|-
 
|-
|Atypical Ductal Hyperplasia||Disease||
+
|Atypical ductal hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 68: Line 69:
 
|
 
|
 
|-
 
|-
|Sclerosing Adenosis||Disease||
+
|Sclerosing adenosis||Disease||
 
|
 
|
 
|
 
|
Line 77: Line 78:
 
|
 
|
 
|-
 
|-
|Apocrine Adenosis and Adenoma||Disease||
+
|Apocrine adenosis and adenoma||Disease||
 
|
 
|
 
|
 
|
Line 86: Line 87:
 
|
 
|
 
|-
 
|-
|Microglandular Adenosis||Disease||
+
|Microglandular adenosis||Disease||
 
|
 
|
 
|
 
|
Line 95: Line 96:
 
|
 
|
 
|-
 
|-
|Radial Scar/Complex Sclerosing Lesion||Disease||
+
|Radial scar/complex sclerosing lesion||Disease||
 
|
 
|
 
|
 
|
Line 104: Line 105:
 
|
 
|
 
|-
 
|-
|Tubular Adenoma||Disease||
+
|Tubular adenoma||Disease||
 
|
 
|
 
|
 
|
Line 113: Line 114:
 
|
 
|
 
|-
 
|-
|Lactating Adenoma||Disease||
+
|Lactating adenoma||Disease||
 
|
 
|
 
|
 
|
Line 122: Line 123:
 
|
 
|
 
|-
 
|-
|Ductal Adenoma||Disease||
+
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|Ductal adenoma||Disease||
 
|
 
|
 
|
 
|
Line 131: Line 143:
 
|
 
|
 
|-
 
|-
|Pleomorphic Adenoma||Disease||
+
|Pleomorphic adenoma||Disease||
 
|
 
|
 
|
 
|
Line 149: Line 161:
 
|
 
|
 
|-
 
|-
|Malignant Adenomyoepithelioma||Disease||
+
|Malignant adenomyoepithelioma||Disease||
 
|
 
|
 
|
 
|
Line 158: Line 170:
 
|
 
|
 
|-
 
|-
|Intraductal Papilloma||Disease||
+
|Intraductal papilloma||Disease||
 
|
 
|
 
|
 
|
Line 167: Line 179:
 
|
 
|
 
|-
 
|-
|Papillary Ductal Carcinoma In Situ||Disease||
+
|Papillary ductal carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 176: Line 188:
 
|
 
|
 
|-
 
|-
|Encapsulated Papillary Carcinoma||Disease||
+
|Encapsulated papillary carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 185: Line 197:
 
|
 
|
 
|-
 
|-
|Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
+
|Solid papillary carcinoma (in situ and invasive)||Disease||
 
|
 
|
 
|
 
|
Line 194: Line 206:
 
|
 
|
 
|-
 
|-
|Invasive Papillary Carcinoma||Disease||
+
|Invasive papillary carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 203: Line 215:
 
|
 
|
 
|-
 
|-
|Atypical Lobular Hyperplasia||Disease||
+
|Atypical lobular hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 212: Line 224:
 
|
 
|
 
|-
 
|-
|Lobular Carcinoma In Situ||Disease||
+
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|Lobular carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 221: Line 244:
 
|
 
|
 
|-
 
|-
|Ductal Carcinoma In Situ||Disease||
+
|Ductal carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 230: Line 253:
 
|
 
|
 
|-
 
|-
|Invasive Breast Carcinoma of No Special Type||Disease||
+
|Invasive breast carcinoma of no special type||Disease||
 
|
 
|
 
|
 
|
Line 239: Line 262:
 
|
 
|
 
|-
 
|-
|Microinvasive Carcinoma||Disease||
+
|Microinvasive carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 248: Line 271:
 
|
 
|
 
|-
 
|-
|Invasive lobular Carcinoma||Disease||
+
|Invasive lobular carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 257: Line 280:
 
|
 
|
 
|-
 
|-
|Tubular Carcinoma||Disease||
+
|Tubular carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 266: Line 289:
 
|
 
|
 
|-
 
|-
|Cribriform Carcinoma||Disease||
+
|Cribriform carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 275: Line 298:
 
|
 
|
 
|-
 
|-
|Mucinous Carcinoma||Disease||
+
|Mucinous carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 284: Line 307:
 
|
 
|
 
|-
 
|-
|Mucinous Cystadenocarcinoma||Disease||
+
|Mucinous cystadenocarcinoma||Disease||
 
|
 
|
 
|
 
|
Line 293: Line 316:
 
|
 
|
 
|-
 
|-
|Invasive Micropapillary Carcinoma||Disease||
+
|Invasive micropapillary carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 302: Line 325:
 
|
 
|
 
|-
 
|-
|Carcinoma with Apocrine Differentiation||Disease||
+
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|Carcinoma with apocrine differentiation||Disease||
 
|
 
|
 
|
 
|
Line 311: Line 345:
 
|
 
|
 
|-
 
|-
|Metaplastic Carcinoma||Disease||
+
|Metaplastic carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 320: Line 354:
 
|
 
|
 
|-
 
|-
|[[BRST5:Acinic Cell Carcinoma|Acinic Cell Carcinoma]]||Disease||Patricija Zot
+
|[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot
 
|2/28/2024
 
|2/28/2024
 
|
 
|
Line 329: Line 363:
 
|
 
|
 
|-
 
|-
|[[BRST5:Adenoid Cystic Carcinoma|Adenoid Cystic Carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
+
|[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
 
|10/12/02022
 
|10/12/02022
 
|11/11/2023
 
|11/11/2023
Line 338: Line 372:
 
|2021 template added
 
|2021 template added
 
|-
 
|-
|[[BRST5:Secretory Carcinoma|Secretory Carcinoma]]||Disease||Hui Chen / Morteza Seifi
+
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi
 
|10/12/2022
 
|10/12/2022
 
|11/11/2023
 
|11/11/2023
Line 347: Line 381:
 
|2021 template added
 
|2021 template added
 
|-
 
|-
|Mucoepidermoid Carcinoma||Disease||
+
|Mucoepidermoid carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 356: Line 390:
 
|
 
|
 
|-
 
|-
|Polymorphous Adenocarcinoma||Disease||
+
|Polymorphous adenocarcinoma||Disease||
 
|
 
|
 
|
 
|
Line 365: Line 399:
 
|
 
|
 
|-
 
|-
|[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall Cell Carcinoma with Reversed Polarity]]||Disease||H. Evin Gulbahce
+
|[[BRST5:Tall cell carcinoma with reversed polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce
 
|8/11/2023
 
|8/11/2023
 
|10/11/2023
 
|10/11/2023
Line 374: Line 408:
 
|2021 template added
 
|2021 template added
 
|-
 
|-
|Neuroendocrine Tumour||Disease||
+
|Neuroendocrine tumour||Disease||
 
|
 
|
 
|
 
|
Line 383: Line 417:
 
|
 
|
 
|-
 
|-
|Neuroendocrine Carcinoma||Disease||
+
|Neuroendocrine carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 392: Line 426:
 
|
 
|
 
|-
 
|-
|CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)
+
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|
 +
====CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)====
 
|
 
|
 
----
 
----
Line 430: Line 476:
 
|2021 template added
 
|2021 template added
 
|-
 
|-
|[[BRST5:Phyllodes Tumour|Phyllodes Tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
+
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
 
|8/11/2023
 
|8/11/2023
 
|11/11/2023
 
|11/11/2023
Line 439: Line 485:
 
|2021 template added
 
|2021 template added
 
|-
 
|-
|CHAPTER 4 (TUMOURS OF THE NIPPLE)
+
|
 +
====CHAPTER 4 (TUMOURS OF THE NIPPLE)====
 
|
 
|
 
----
 
----
Line 459: Line 506:
 
----
 
----
 
|-
 
|-
|Syringomatous Tumour||Disease||
+
|Syringomatous tumour||Disease||
 
|
 
|
 
|
 
|
Line 468: Line 515:
 
|
 
|
 
|-
 
|-
|Nipple Adenoma||Disease||
+
|Nipple adenoma||Disease||
 
|
 
|
 
|
 
|
Line 477: Line 524:
 
|
 
|
 
|-
 
|-
|Paget disease of the Breast||Disease||
+
|Paget disease of the breast||Disease||
 
|
 
|
 
|
 
|
Line 486: Line 533:
 
|
 
|
 
|-
 
|-
|CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)
+
|
 +
====CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)====
 
|
 
|
 
----
 
----
Line 514: Line 562:
 
|
 
|
 
|
 
|
 +
|-
 +
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 
|-
 
|-
 
|Angiomatosis||Disease||
 
|Angiomatosis||Disease||
Line 524: Line 583:
 
|
 
|
 
|-
 
|-
|Atypical Vascular Lesions||Disease||
+
|Atypical vascular lesions||Disease||
 
|
 
|
 
|
 
|
Line 533: Line 592:
 
|
 
|
 
|-
 
|-
|Postradiation Angiosarcoma of the Breast||Disease||
+
|Postradiation angiosarcoma of the breast||Disease||
 
|
 
|
 
|
 
|
Line 542: Line 601:
 
|
 
|
 
|-
 
|-
|Primary Angiosarcoma of the Breast||Disease||
+
|Primary angiosarcoma of the breast||Disease||
 
|
 
|
 
|
 
|
Line 551: Line 610:
 
|
 
|
 
|-
 
|-
|Nodular Fasciitis||Disease||
+
|Nodular fasciitis||Disease||
 
|
 
|
 
|
 
|
Line 569: Line 628:
 
|
 
|
 
|-
 
|-
|Desmoid Fibromatosis||Disease||
+
|Desmoid fibromatosis||Disease||
 
|
 
|
 
|
 
|
Line 578: Line 637:
 
|
 
|
 
|-
 
|-
|[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory Myofibroblastic Tumour]]||Disease||Yajuan Liu
+
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu
 
|8/11/2023
 
|8/11/2023
 
|11/11/2023
 
|11/11/2023
Line 605: Line 664:
 
|
 
|
 
|-
 
|-
|Granular Cell Tumour||Disease||
+
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|Granular cell tumour||Disease||
 
|
 
|
 
|
 
|
Line 659: Line 729:
 
|
 
|
 
|-
 
|-
|Pseudoangiomatous Stromal Hyperplasia||Disease||
+
|Pseudoangiomatous stromal hyperplasia||Disease||
 
|
 
|
 
|
 
|
Line 668: Line 738:
 
|
 
|
 
|-
 
|-
|CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)
+
|
 +
====CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)====
 
|
 
|
 
----
 
----
Line 688: Line 759:
 
----
 
----
 
|-
 
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
+
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
 
|
 
|
 
|
 
|
Line 697: Line 768:
 
|
 
|
 
|-
 
|-
|Follicular Lymphoma||Disease||
+
|Follicular lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 706: Line 777:
 
|
 
|
 
|-
 
|-
|Diffuse Large B-cell Lymphoma||Disease||
+
!'''Disease'''
 +
!'''Page Type'''
 +
!'''<span style="color:#0070C0">Author'''
 +
!'''Date Assigned to Author'''
 +
!'''Target Completion Date'''
 +
!'''Author Content (Pending or Complete)'''
 +
!'''Date Completed by Author'''
 +
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|Diffuse large B-cell lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 715: Line 797:
 
|
 
|
 
|-
 
|-
|Burkitt Lymphoma||Disease||
+
|Burkitt lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 724: Line 806:
 
|
 
|
 
|-
 
|-
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
+
|Breast implant-associated anaplastic large cell lymphoma||Disease||
 
|
 
|
 
|
 
|
Line 733: Line 815:
 
|
 
|
 
|-
 
|-
|CHAPTER 7 (TUMOURS OF THE MALE BREAST)
+
|
 +
====CHAPTER 7 (TUMOURS OF THE MALE BREAST)====
 
|
 
|
 
----
 
----
Line 762: Line 845:
 
|
 
|
 
|-
 
|-
|Carcinoma In Situ||Disease||
+
|Carcinoma in situ||Disease||
 
|
 
|
 
|
 
|
Line 771: Line 854:
 
|
 
|
 
|-
 
|-
|Invasive Carcinoma||Disease||
+
|Invasive carcinoma||Disease||
 
|
 
|
 
|
 
|
Line 780: Line 863:
 
|
 
|
 
|-
 
|-
|Metastases to the Breast||Disease||
+
|Metastases to the breast||Disease||
 
|
 
|
 
|
 
|
Line 789: Line 872:
 
|
 
|
 
|-
 
|-
|CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)
+
|
 +
====CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)====
 
|
 
|
 
----
 
----
Line 809: Line 893:
 
----
 
----
 
|-
 
|-
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:BRCA1/2-associated hereditary breast and ovarian cancer syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 818: Line 902:
 
|N/A
 
|N/A
 
|-
 
|-
|Cowden Syndrome||Disease||
+
!'''Disease'''
|
+
!'''Page Type'''
|
+
!'''<span style="color:#0070C0">Author'''
|
+
!'''Date Assigned to Author'''
|
+
!'''Target Completion Date'''
|
+
!'''Author Content (Pending or Complete)'''
|
+
!'''Date Completed by Author'''
|NOT YET CREATED (not in GTS5) - See page "[[DIG5:Cowden syndrome|Cowden Syndrome]]" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - [[DIG5:Volunteer Assignments and Opportunities]]).
+
!'''Associate Editor'''
 +
!'''Date of Last Editor Review'''
 +
!'''Notes'''
 +
|-
 +
|[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 +
|N/A
 
|-
 
|-
|Ataxia-Telangiectasia||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 836: Line 931:
 
|N/A
 
|N/A
 
|-
 
|-
|Li-Fraumeni Syndrome, TP53-Associated||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 845: Line 940:
 
|N/A
 
|N/A
 
|-
 
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni Syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 854: Line 949:
 
|N/A
 
|N/A
 
|-
 
|-
|CDH1-Associated Breast Cancer||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 863: Line 958:
 
|N/A
 
|N/A
 
|-
 
|-
|PALB2-Associated Cancers||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 872: Line 967:
 
|N/A
 
|N/A
 
|-
 
|-
|Peutz-Jeghers Syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
+
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
 
|N/A
 
|N/A
 
|N/A
 
|N/A
Line 881: Line 976:
 
|N/A
 
|N/A
 
|-
 
|-
|Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
+
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
+
|N/A
|
+
|N/A
|
+
|N/A
|
+
|N/A
|
+
|N/A
|
+
|N/A
|NOT YET CREATED - See page "[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]).
+
|N/A
 
|-
 
|-
|[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic Component of Breast Cancer Susceptibility]]
+
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
 
|Disease
 
|Disease
 
|Xiaolin Hu
 
|Xiaolin Hu

Latest revision as of 13:52, 10 September 2024

Welcome!

For assignments, please see the "Author" column below (highlighted blue).

If empty (no name is present), please volunteer to create content for that disease!

To volunteer, please [Contact us] with your page of interest.


WHO Classification of Tumours of the Breast (5th Edition) Content
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes

CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)










Usual ductal hyperplasia Disease
Columnar cell lesions, including flat epithelial atypia Disease
Atypical ductal hyperplasia Disease
Sclerosing adenosis Disease
Apocrine adenosis and adenoma Disease
Microglandular adenosis Disease
Radial scar/complex sclerosing lesion Disease
Tubular adenoma Disease
Lactating adenoma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Ductal adenoma Disease
Pleomorphic adenoma Disease
Adenomyoepithelioma Disease
Malignant adenomyoepithelioma Disease
Intraductal papilloma Disease
Papillary ductal carcinoma in situ Disease
Encapsulated papillary carcinoma Disease
Solid papillary carcinoma (in situ and invasive) Disease
Invasive papillary carcinoma Disease
Atypical lobular hyperplasia Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Lobular carcinoma in situ Disease
Ductal carcinoma in situ Disease
Invasive breast carcinoma of no special type Disease
Microinvasive carcinoma Disease
Invasive lobular carcinoma Disease
Tubular carcinoma Disease
Cribriform carcinoma Disease
Mucinous carcinoma Disease
Mucinous cystadenocarcinoma Disease
Invasive micropapillary carcinoma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Carcinoma with apocrine differentiation Disease
Metaplastic carcinoma Disease
Acinic cell carcinoma Disease Patricija Zot 2/28/2024 PENDING Katherine Geiersbach
Adenoid cystic carcinoma Disease Katherine Geiersbach / Jun Liao 10/12/02022 11/11/2023 COMPLETE Hui Chen / Katherine Geiersbach 12/6/2023 2021 template added
Secretory carcinoma Disease Hui Chen / Morteza Seifi 10/12/2022 11/11/2023 COMPLETE Katherine Geiersbach 2021 template added
Mucoepidermoid carcinoma Disease
Polymorphous adenocarcinoma Disease
Tall cell carcinoma with reversed polarity Disease H. Evin Gulbahce 8/11/2023 10/11/2023 COMPLETE Katherine Geiersbach 2021 template added
Neuroendocrine tumour Disease
Neuroendocrine carcinoma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes

CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)










Hamartoma Disease
Fibroadenoma Disease H. Evin Gulbahce / Patricija Zot 8/11/2023 11/11/2023 PENDING 2021 template added
Phyllodes tumour Disease Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach 8/11/2023 11/11/2023 COMPLETE 2021 template added

CHAPTER 4 (TUMOURS OF THE NIPPLE)










Syringomatous tumour Disease
Nipple adenoma Disease
Paget disease of the breast Disease

CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)










Haemangioma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Angiomatosis Disease
Atypical vascular lesions Disease
Postradiation angiosarcoma of the breast Disease
Primary angiosarcoma of the breast Disease
Nodular fasciitis Disease
Myofibroblastoma Disease
Desmoid fibromatosis Disease
Inflammatory myofibroblastic tumour Disease Yajuan Liu 8/11/2023 11/11/2023 COMPLETE Katherine Geiersbach 12/6/2023 2021 template added
Schwannoma Disease
Neurofibroma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Granular cell tumour Disease
Leiomyoma Disease
Leiomyosarcoma Disease
Lipoma Disease
Angiolipoma Disease
Liposarcoma Disease
Pseudoangiomatous stromal hyperplasia Disease

CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)










Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Disease
Follicular lymphoma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Diffuse large B-cell lymphoma Disease
Burkitt lymphoma Disease
Breast implant-associated anaplastic large cell lymphoma Disease

CHAPTER 7 (TUMOURS OF THE MALE BREAST)










Gynaecomastia Disease
Carcinoma in situ Disease
Invasive carcinoma Disease
Metastases to the breast Disease

CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)










BRCA1/2-associated hereditary breast and ovarian cancer syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Cowden syndrome Disease See DIG5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Ataxia-telangiectasia Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Li-Fraumeni syndrome, TP53-associated Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Li-Fraumeni syndrome, CHEK2-associated Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
CDH1-associated breast cancer Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
PALB2-associated cancers Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Peutz-Jeghers syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Neurofibromatosis type 1 Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Polygenic component of breast cancer susceptibility Disease Xiaolin Hu 6/4/2024 Template added (6/4/24)